Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families
June 27, 2023 07:00 ET
|
Black Diamond Therapeutics, Inc
BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for MasterKey mutation-targeting approach based on radiographic tumor responses and...
Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer
June 13, 2023 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies...
Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference
June 02, 2023 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies...
Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 09, 2023 07:30 ET
|
Black Diamond Therapeutics, Inc
On track to provide clinical update from dose-escalation portion of Phase 1 clinical trial of EGFR MasterKey inhibitor BDTX-1535 in the second half of 2023; Dose Expansion cohorts expected to open in...
Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days
April 18, 2023 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies...
Black Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual Meeting
April 17, 2023 16:01 ET
|
Black Diamond Therapeutics, Inc
BDTX-1535 Phase 1 dose escalation ongoing in NSCLC harboring sensitizing EGFR mutations with or without CNS disease and recurrent GBM expressing EGFR alterations; Dose expansion cohorts expected to...
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 09, 2023 07:30 ET
|
Black Diamond Therapeutics, Inc
On track to provide clinical update from dose-escalation portion of Phase 1 clinical trial of EGFR MasterKey inhibitor BDTX-1535 in the second half of 2023 FDA clearance of IND application for...
Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
February 27, 2023 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, NY, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing novel MasterKey...
Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies...
Black Diamond Therapeutics Announces Changes to Board of Directors
December 19, 2022 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...